Showing results (81-90 of 144) with videos related to

Sort By:
Pageof 15
Cancer Immunology Research|October 18, 2017
Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor RecurrenceTim Kottke, Laura Evgin, Kevin G Shim, et al.
Cancers|February 25, 2022
A Comprehensive Review of the Current and Future Role of the Microbiome in Pancreatic Ductal AdenocarcinomaNabeel Merali, Tarak Chouari, Kayani Kayani, et al.
Experimental Biology and Medicine (Maywood, N.J.)|March 11, 2024
A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanismsNahid Zareian, Oleg Eremin, Hardev Pandha, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 26, 2014
The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical siteVanesa Alonso-Camino, Karishma Rajani, Timothy Kottke, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2013
Expression of Engrailed-2 (EN2) protein in bladder cancer and its potential utility as a urinary diagnostic biomarkerRichard Morgan, Richard T Bryan, Saqib Javed, et al.
Molecular Therapy Oncolytics|December 10, 2016
Immunogenicity of self tumor associated proteins is enhanced through protein truncationTim Kottke, Kevin G Shim, Vanesa Alonso-Camino, et al.
Cancers|February 25, 2023
A Novel Blood Proteomic Signature for Prostate CancerAmmara Muazzam, Matt Spick, Olivier N F Cexus, et al.
ESMO Open|February 22, 2020
Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised studyDavid Lau, Eleftheria Kalaitzaki, David N Church, et al.
BMC Cancer|April 14, 2022
HOX and PBX gene dysregulation as a therapeutic target in glioblastoma multiformeEinthavy Arunachalam, William Rogers, Guy R Simpson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 27, 2015
BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER StressVictoria Roulstone, Malin Pedersen, Joan Kyula, et al.
Pageof 15